Investors looking to evaluate opportunities in the medical device sector may find themselves comparing two notable companies: Pro-Dex and STAAR Surgical. Both firms are small-cap players on the NASDAQ, but they offer different prospects in terms of valuation, earnings, risk, and profitability.
Institutional and Insider Ownership
A significant difference between Pro-Dex and STAAR Surgical lies in their ownership structures. Approximately 15.3% of Pro-Dex shares are held by institutional investors, indicating a level of interest from large money managers. In stark contrast, 96.7% of STAAR Surgical shares are owned by institutional investors, suggesting a strong belief among these entities that STAAR will outperform the market in the long term.
When it comes to insider ownership, 45.9% of Pro-Dex shares are owned by company insiders, compared to a mere 0.6% of STAAR Surgical shares. This higher insider ownership at Pro-Dex could reflect greater confidence from those closely involved with the company.
Valuation and Earnings Performance
In terms of financial performance, Pro-Dex showcases higher earnings but generates less revenue than STAAR Surgical. While Pro-Dex has outperformed STAAR in earnings per share, the latter has a larger revenue base. Notably, STAAR Surgical is currently trading at a lower price-to-earnings ratio, marking it as the more affordable option among the two.
Analysts have provided differing outlooks on the two companies. Pro-Dex holds a consensus price target of $56.00, indicating a potential upside of 43.15%. On the other hand, STAAR Surgical has a lower consensus price target of $20.68, which suggests a modest potential upside of 8.04%. These figures lead analysts to favor Pro-Dex as the more attractive investment.
Risk Assessment and Volatility
When assessing risk, Pro-Dex demonstrates a beta of -0.05, indicating that its stock price is significantly less volatile than the broader market, specifically 105% less volatile than the S&P 500. STAAR Surgical, with a beta of 1, shows a volatility profile comparable to that of the S&P 500. This distinction may appeal to risk-averse investors considering their options.
Profitability and Summary
A comparative analysis of profitability metrics reveals that Pro-Dex surpasses STAAR Surgical in ten of the fourteen factors reviewed. This includes net margins and returns on equity and assets, further solidifying Pro-Dex’s stance as a potentially more robust investment.
Founded in 1978 and headquartered in Irvine, California, Pro-Dex, Inc. specializes in the design and manufacture of powered surgical instruments for various medical applications. Its products are utilized in fields such as orthopedics and thoracic surgery. In contrast, STAAR Surgical, established in 1982 and based in Lake Forest, California, focuses on developing implantable lenses for eye care, catering primarily to ophthalmologists and surgical centers.
In conclusion, while both Pro-Dex and STAAR Surgical operate within the medical device sector, their financial profiles and market positions differ significantly. Investors may find Pro-Dex to be the more favorable choice based on its earnings strength, insider ownership, and risk profile, while STAAR Surgical still holds appeal due to its established revenue base and institutional backing.
